Treating Immunodeficiency through HSC Gene Therapy

Slides:



Advertisements
Similar presentations
The emperor's new dystrophin: finding sense in the noise S.D. Wilton, R.N. Veedu, S. Fletcher Trends in Molecular Medicine Volume 21, Issue 7, Pages
Advertisements

Gene therapy progress and prospects cancer. Gene Therapy Primary challenge for gene therapy – Successfully delivery an efficacious dose of a therapeutic.
Gene therapy Fabrizia Urbinati 01/12/2010.
Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair Francesco S. Loffredo, Matthew L. Steinhauser,
Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein Stefano Angiari, Gabriela Constantin Trends in Molecular.
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease Simone Becattini, Ying Taur, Eric G. Pamer Trends in Molecular Medicine Volume 22,
Volume 17, Issue 6, Pages (June 2009)
Lenograstim Chemical Formula : C840-H1330-N222-O242-S8
Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
Volume 19, Issue 1, Pages (January 2011)
Pluripotent stem cell based gene therapy for hematological diseases
Advancing Stem Cell Biology toward Stem Cell Therapeutics
Chemotherapy and Cancer Stem Cells
Constitutively Active β-Catenin Confers Multilineage Differentiation Potential on Lymphoid and Myeloid Progenitors  Yoshihiro Baba, Karla P. Garrett,
Volume 18, Issue 1, Pages (January 2016)
Volume 22, Issue 3, Pages (March 2014)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 17, Issue 11, Pages (November 2009)
Adrian G. Selim, Andrew S. Moore  The Journal of Molecular Diagnostics 
Genetics and Genomics in the Practice of Medicine
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Volume 17, Issue 9, Pages (September 2009)
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Immune-Cell Lineage Commitment: Translation from Mice to Humans
Evolving Gene Therapy in Primary Immunodeficiency
DNA CLONING IN CANCER TREATMENT : GENE INFUSION (CAR-T Therapy)
Volume 20, Issue 5, Pages (May 2012)
PU.1 Takes Control of the Dendritic Cell Lineage
Volume 23, Issue 5, Pages (May 2015)
Gene therapy returns to centre stage
Donald B. Kohn, MD, Caroline Y. Kuo, MD 
Volume 381, Issue 9875, Pages (April 2013)
Volume 12, Issue 3, Pages (September 2005)
Volume 20, Issue 5, Pages (May 2012)
Gene Therapy Researchers' Assessments Of Risks And Perceptions Of Risk Acceptability In Clinical Trials  Claire T. Deakin, Ian E. Alexander, Cliff A.
Dendritic Cell Therapies for Hematologic Malignancies
Luca Biasco, Michael Rothe, Hildegard Büning, Axel Schambach 
Global Manufacturing of CAR T Cell Therapy
Volume 25, Issue 8, Pages (August 2017)
Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals  Clare Pridans,
Volume 19, Issue 1, Pages (January 2011)
Volume 20, Issue 10, Pages (October 2012)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
CRISPR/Cas9: A Potential Life-Saving Tool. What’s next?
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Volume 5, Issue 5, Pages (November 2015)
Moonjung Jung, Cynthia E Dunbar, Thomas Winkler  Molecular Therapy 
Volume 15, Issue 8, Pages (August 2007)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 19, Issue 5, Pages (May 2011)
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Volume 21, Issue 1, Pages (January 2013)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 4, Pages (April 2015)
Volume 19, Issue 1, Pages (January 2011)
Mary Eapen  Biology of Blood and Marrow Transplantation 
Searching for leukemia stem cells—Not yet the end of the road?
Volume 21, Issue 5, Pages (May 2013)
Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease
Engineering Globin Gene Expression
Memoirs of a Reincarnated T Cell
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Presentation transcript:

Treating Immunodeficiency through HSC Gene Therapy Claire Booth, H. Bobby Gaspar, Adrian J. Thrasher  Trends in Molecular Medicine  Volume 22, Issue 4, Pages 317-327 (April 2016) DOI: 10.1016/j.molmed.2016.02.002 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Key Figure: Haematopoietic Stem Cell (HSC) Gene Therapy HSCs are harvested from a patient either through bone marrow (BM) harvest or leukapheresis of mobilised peripheral blood stem cells (PBSCs). CD34+ cells are selected using magnetic separation columns and cultured with cytokines [usually IL-3, stem cell factor (SCF), thrombopoietin (TPO), and Flt-3 ligand] before transduction with a specific viral vector. The length of the transduction protocol varies according to the disease and the vector. After a period of culture, transduced CD34+ cells are re-infused into the patient, who may have received cytoreductive or myeloablative chemotherapy to secure engraftment of gene-corrected haematopoietic progenitors in the BM niche. Again, the intensity of conditioning at this stage varies with each disease. Initial trials have utilised gammaretroviral (γRV) vectors with corrective cDNA expression under the control of viral promoters in the 5′ and 3′ long terminal repeats (LTRs). However, adverse events related to vector design have led to the development and utilisation of self-inactivating (SIN)-γRV vectors and, subsequently, SIN-lentiviral (SIN-LV) vectors in which deleterious LTRs have been mutated and appropriate transgene expression (driven by internal mammalian promoters) has been allowed to ensue. In later vector designs, the transgene cDNA has sometimes been codon optimised (CO cDNA) to further improve gene expression. Trends in Molecular Medicine 2016 22, 317-327DOI: (10.1016/j.molmed.2016.02.002) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Potential Factors Leading to Improved Safety and Efficacy of Haematopoietic Stem Cell (HSC) Gene Therapy. Developments in three main areas have the potential to improve both the safety and the efficacy of HSC gene therapy. Greater accessibility to treatment will allow more patients to be treated, thereby generating substantial data that can be used to further understand the effect of variables such as cell dose and levels of engraftment on outcome. This, along with the incorporation of technological advances – for example, those related to integration site analysis – will also help improve our understanding of factors affecting both safety and efficacy. In the long term, the rapid rise of gene editing platforms capable of precisely correcting gene defects will undoubtedly play a greater role in improving the safety and efficacy of gene therapy procedures. Trends in Molecular Medicine 2016 22, 317-327DOI: (10.1016/j.molmed.2016.02.002) Copyright © 2016 Elsevier Ltd Terms and Conditions